SHANGHAI – Denovo Biopharma LLC, a cross-border biotech with offices in San Diego and Shanghai, has dosed the first patient in a phase III trial of DB-102 (enzastaurin) to treat diffuse large B-cell lymphoma (DLBCL). DB-102 is a serine/threonine kinase inhibitor of the PKC beta and AKT pathways.